Q&A with Christopher Meissner, Meissner - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Christopher Meissner, Meissner
Christopher Meissner, CEO of Meissner Filtration Products, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 6, pp. 72

Q&A with
Christopher Meissner, CEO of Meissner Filtration Products


Christopher Meissner
PharmTech:
How do you stay abreast of new developments in the industry?

Meissner:
The Internet is a huge boon that really increases our ability to link our clients, our sales teams, and our engineering teams. Of course, this creates challenges in itself just to prevent important developments from being lost in background noise. We mitigate much of this problem with good teamwork and good tools, but at the end of the day there's no substitute for continuous and direct contact with clients.

PharmTech:
Do you see a new industry trend emerging?

Meissner:
As medicines and treatments become more individually focused, and drugs are more specifically targeted, their manufacture increases in complexity, requiring greater levels of safety. Many active pharmaceutical ingredients use chemicals that require extreme efforts to minimize operator exposure, and more efficient methods of managing these processes are required. Product innovations, such as disposable filter assemblies that isolate operators not only from fluid contact, but also from vapor contact when they are changing filters, provide a way in which these chemicals can be handled safely and produced efficiently.

PharmTech:
What is the most common demand your clients are currently making of you?

Meissner:
Custom-engineered solutions for clients often require a significant amount of time for approval. Many times, approval is pushed through only days before product is needed by manufacturing. Our most common request is to expedite the delivery of these developed solutions. In addition, each client often has a slightly different approach for mitigating risk associated with any change, and we see a corresponding increase in requests for new and innovative solutions to meet their approaches.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here